期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

直接凝血酶抑制药希美加群在心房颤动抗凝治疗中的应用 被引量：3

Anticoagulant effect of direct thrombin inhibitor ximelagatran on atrial fibrillation
下载PDF
导出
摘要 希美加群是一种直接凝血酶抑制药,具有抑制作用强、治疗窗口宽、为可逆性抑制、对游离的和与血栓结合的凝血酶均有抑制作用、起效较快等优点,在心房颤动抗凝治疗中发挥重要作用。 Ximelagatran is a direct thrombin inhibitor and is able to inhibit both free and clot-bound thrombin with the advantages of strong inhibition effect, wide therapeutic window, reversible inhibition and short response time. It plays an important role in the treatment of atrial fibrillation.
作者 黄震华
机构地区 上海交通大学医学院附属第九人民医院心血管病研究室
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2008年第7期527-530,共4页 Chinese Journal of New Drugs and Clinical Remedies
关键词 心房颤动 抗凝药 凝血酶 希美加群 atrial fibrillation anticoagulants thrombin ximelagatran
分类号 R972.7 [医药卫生—药品] R541.75 [医药卫生—心血管疾病]
  • 相关文献

参考文献21

  • 1LLOYD-JONES DM, WANG TJ, LEIP EP, et al. Lifetime risk for development of atrial fibrillation: Framingham Heart study[J]. Circulation, 2004, 110(9): 1042-1046.
  • 2FEINBERG WM, BLACKSHEAR JL, LAUPACIS A, et al. Prevalence, age distribution and gender of patients with atrial fibrillation[J]. Arch Intern Med, 1995, 155(5):469-473.
  • 3STEINBERG JS. Atrial fibrillation: an emerging epidemic? [J].Heart, 2004, 90(3): 239-240.
  • 4ALBERS GW, DALEN jE, LAUPACIS A, et al. Antithrombotic therapy in atrial fibrillation[J]. Chest, 2001, 119 (1 Suppl): 194S-206S.
  • 5HART RG. Atrial fibrillation and stroke prevention[J]. N Engl J Med, 2003, 349(11 ) : 1015-1016.
  • 6HART RG, PALACIO S, PEARCE LA. Atrial fibrillation, stroke, and acute antithrombotic therapy: analysis of randomized clinical trials[J]. Stroke, 2002, 33(11): 2722- 2727.
  • 7HALPERIN JL. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation[J]. J Am Coll Cardiol, 2005, 45 ( 1 ) : 1-9.
  • 8GUSTAFSSON D, BYLUND R, ANTONSSON T, et al. A new oral anticoagulant: the 50-year challenge [J]. Nat Rev Drug Discov, 2004, 3(8):649-659.
  • 9WOLZT M, BOSTROM SL, SVENSSON M, et al. Effects of the oral direct thrombin inhibitor ximelagatran on P-selectin expression and thrombin generation in atrial fibrillation [J]. Pathophysiol Haemost Thromb, 2003, 33(2) : 68-74.
  • 10GUSTAFSSOND, NYSTROM J, CARLSSON S, et al. The direct thrombin inhibitor melagatran and its oral prodrug H376/ 95: intestinal absorption properties, biochemical and pharmacodynamic effects[J]. Thromb Res, 2001, 101(3): 171- 181.

同被引文献54

  • 1丽英,杨艳敏.抗血小板药物在心房颤动抗栓治疗中的应用[J].中国心脏起搏与心电生理杂志,2006,20(1):85-87. 被引量：5
  • 2韩雅玲,王祖禄.心房颤动患者血栓栓塞并发症的防治[J].中国实用内科杂志,2006,26(2):177-179. 被引量：34
  • 3李天民,郑慧雅.房颤抗凝治疗的现状与进展[J].河北北方学院学报（医学版）,2007,24(1):70-72. 被引量：5
  • 4李爱民,黄岚.应当重视心房颤动的规范化抗栓治疗[J].西部医学,2007,19(3):329-331. 被引量：3
  • 5Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke : The Framingham Study [ J ]. Stroke, 1991,22 ( 8 ) :983 -988.
  • 6Petersen P, Boysen G, Gootfredsen J, et al. Randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study [ J ]. Lancet, 1989,1 ( 8631 ) : 175 -179.
  • 7No authors listed. Stroke prevention in atrial fibrillation study. Final results [ J ]. Circulation, 1991,84 ( 2 ) : 527 -539.
  • 8The Boston area anticoagulation trial for atrial fibrillation investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation[ J]. N Engl J Med,1990,323(22) :1505-1511.
  • 9Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans affairs stroke prevention in nonrheumatic atrial fibrillation investigators [ J]. N Engl J Med, 1990, 328 (2) : 148-152.
  • 10Connolly SJ, Laupacis A, Canadian G. Atrial Fibrillation Anticoagulation ( CAFA ) study [ J ]. J Am Coll Cardiol, 1991,18 ( 2 ) : 349 -355.

引证文献3

二级引证文献11

中国新药与临床杂志
2008年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部